Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
Kato, K. Yoon, H. Raymond, E. Hubner, Richard A Shu, Y. Pan, Y. Park, S. R. Ping, L. Jiang, Y. Zhang, J.
Kato, K.
Yoon, H.
Raymond, E.
Hubner, Richard A
Shu, Y.
Pan, Y.
Park, S. R.
Ping, L.
Jiang, Y.
Zhang, J.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Kato K, Yoon H, Raymond E, Hubner R, Shu Y, Pan Y, et al. Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup. Annals of Oncology. 2022 Nov;38(9):S1458-S. PubMed PMID: WOS:000897943700072.